Kelly Mercier, Ph.D (@kellymercierph1) 's Twitter Profile
Kelly Mercier, Ph.D

@kellymercierph1

Med affairs lead for Dx; Duke adjunct; PI. Mom of 2 boys & newlywed to Army vet. Tweets are my own, retweets are not endorsements. Personal account. GO BIG RED.

ID: 1135214076542562304

calendar_today02-06-2019 15:58:21

3,3K Tweet

657 Followers

580 Following

Lung Cancers Today (@lung_cancers) 's Twitter Profile Photo

🌟Thanks to Matthew Smeltzer of University of Memphis for a great interview on his #ASCO25 poster presentation about biomarker testing of lung cancer in North America versus globally! ➡️Stop by poster #21 through 4:30 p.m. today to see the data and stay tuned for the interview! #lcsm

🌟Thanks to <a href="/MattSmeltzer/">Matthew Smeltzer</a> of <a href="/uofmemphis/">University of Memphis</a> for a great interview on his #ASCO25 poster presentation about biomarker testing of lung cancer in North America versus globally! 

➡️Stop by poster #21 through 4:30 p.m. today to see the data and stay tuned for the interview! 

#lcsm
Hossein Borghaei, DO (@hosseinborghaei) 's Twitter Profile Photo

Proud to see Dr Padda presenting the results of the S1900E. This is yet another example of how we can all come together and conduct national trials in rare subtypes of NSCLC and answer important questions quickly. #lungmap , #ASCO , #FoxChaseCancer

Proud to see Dr Padda presenting the results of the S1900E. This is yet another example of how we can all come together and conduct national trials in rare subtypes of NSCLC and answer important questions quickly. #lungmap , #ASCO , #FoxChaseCancer
Kelly Mercier, Ph.D (@kellymercierph1) 's Twitter Profile Photo

The Lung-MAP study that prospectively evaluated co-mutations with KRAS G12C therapy to understand outcomes compared to doce. Sukhmani (Suki) Padda MD The cohorts can’t be compared to the others, but it is interesting to see trends with this study with the registrational studies. #ASCO2025

The Lung-MAP study that prospectively evaluated co-mutations with KRAS G12C therapy to understand outcomes compared to doce. <a href="/SukiPaddaMD/">Sukhmani (Suki) Padda MD</a> 
The cohorts can’t be compared to the others, but it is interesting to see trends with this study with the registrational studies. #ASCO2025
Jill Feldman (@jillfeldman4) 's Twitter Profile Photo

It's that time! If you are a fellow, Jr faculty, or post doc doing research in #EGFR #lungcancer, submit your abstract for a chance to join us in Chicago, Nov 6-8, at the EGFR Resisters Research Summit. Great opportunity to network with thought leaders in #lungcancer, other

David Gandara (@drgandara) 's Twitter Profile Photo

At NOSCM, Julia Rotow MD presents provocative data supporting continuation of EGFR TKIs after progressive disease, so-called treatment beyond progression (TBP). I am increasingly a believer. Invariably there are residual sensitive clones which need to be controlled

At NOSCM, <a href="/JuliaRotow/">Julia Rotow MD</a>  presents provocative data supporting continuation of EGFR TKIs after progressive disease, so-called treatment beyond progression (TBP). I am increasingly a believer. Invariably there are residual sensitive clones which need to be controlled
Kelly Mercier, Ph.D (@kellymercierph1) 's Twitter Profile Photo

I am thrilled to be joining the #ilcc2025 in person again! I’ll try to share all the important biomarker and diagnostic learnings for #lungcancer.

I am thrilled to be joining the #ilcc2025 in person again! I’ll try to share all the important biomarker and diagnostic learnings for #lungcancer.
Kelly Mercier, Ph.D (@kellymercierph1) 's Twitter Profile Photo

In the early or locally advanced #NSCLC, we can use liquid phase of FNA or cytology smears to get answers quickly via #pcr prior to treatment decisions. Ignacio Wistuba, MD #ilcc2025

In the early or locally advanced #NSCLC, we can use liquid phase of FNA or cytology smears to get answers quickly via #pcr prior to treatment decisions. <a href="/MdWistuba/">Ignacio Wistuba, MD</a> #ilcc2025
Balazs Halmos (@balazshalmosmd) 's Twitter Profile Photo

Hey @iaslc thoracic friends! Make sure to join in Barcelona for a fantastic early career investigator workshop Dr. Bar w co-chairs Drs. Jiwnani/ Deng and Leal really raised the bar- this session will have everything ☑️study design ☑️career strategies ☑️grant applications

IASLC (@iaslc) 's Twitter Profile Photo

Only 1 Week Left! 🕞 Want to co-lead WCLC 2027 in Denver? Applications for Conference Co-Chairs close on August 6. Don’t miss your chance to be at the forefront of lung cancer research and care. Apply now! bit.ly/3JbPpkF #conference #cochairs #denver #lungcancer #IASLC

Only 1 Week Left! 🕞
Want to co-lead WCLC 2027 in Denver? Applications for Conference Co-Chairs close on August 6. Don’t miss your chance to be at the forefront of lung cancer research and care. Apply now! bit.ly/3JbPpkF 

#conference #cochairs #denver #lungcancer #IASLC
Kelly Mercier, Ph.D (@kellymercierph1) 's Twitter Profile Photo

The current status is how our government is managing social determinants (drivers) of health for oncology was highlighted by Dr Alyssa Schatz (National Comprehensive Cancer Network (NCCN)). So many cuts to programs that support screening patients, feeding patients, and other services. #bestofasco Dr. Luis E. Raez

The current status is how our government is managing social determinants (drivers) of health for oncology was highlighted by Dr Alyssa Schatz (<a href="/NCCN/">National Comprehensive Cancer Network (NCCN)</a>). So many cuts to programs that support screening patients, feeding patients, and other services. #bestofasco <a href="/LuisRaezMD/">Dr. Luis E. Raez</a>